Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression. Foscarnet induction therapy was administered at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days. Foscarnet maintenance therapy was administered at a dosage of 90 mg/kg/day via 2-hour infusion. Foscarnet was well tolerated and effective in delaying progression of CMV retinitis in these patients. Final analysis of data from this study and data from other studies will help to determine what role foscarnet will have in the treatment of CMV retinitis in patients with AIDS.
Polis
M A
MA
National Institutes of Health, Bethesda, Maryland 20892.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology; D015828:Eye Infections, Viral / Q000188:drug therapy* / Q000209:etiology; D017245:Foscarnet; D006801:Humans; D008297:Male; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012173:Retinitis / Q000188:drug therapy* / Q000209:etiology
D000998:Antiviral Agents; D017245:Foscarnet; D010746:Phosphonoacetic Acid